Women's Health

Highlights include time-efficient strategies for primary care clinicians to identify, assess, and treat GSM and other sexual health concerns during menopause.

ACOG 2026: Kathryn Miele, MD, discusses syphilis screening in pregnancy and how clinicians can reduce stigma around testing.

ACOG 2026: Kathryn Miele, MD, discusses syphilis titer interpretation, discordant results, partner treatment, and practical resources for primary care clinicians.

Highlights include clinical gaps in menopause care, postpartum prevention, cervical cancer screening, pregnancy-related infection, and GLP-1 RA exposure.

Pneumococcal vaccination in pregnancy remains underused in high-risk patients. Maria Marcos, MD, reviews new data, barriers to uptake, and practical vaccination steps for primary care.

Jill Liss, MD, outlines how updated evidence, risk stratification, and newer nonhormonal agents can help PCPs confidently manage VMS in everyday practice.

ACOG 2026: James A. Simon, MD, discusses off-label evidence for elinzanetant in breast cancer survivors on anti-estrogenic therapy.

ACOG 2026: James A. Simon, MD, discusses what the results mean for frontline clinician confidence in prescribing the non-hormonal VMS treatment.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Late-breaking data presented at ACOG 2026 showed GLP-1 RA exposure before or during early pregnancy was not associated with hypertensive disorders of pregnancy.

ACOG 2026: Jill Liss, MD, details how primary care physicians can safely initiate hormone therapy, manage menopause counseling in brief visits, and more.

ACOG 2026: The new guidance formally introduces clinician-ordered self-collected HPV testing as an option for cervical cancer screening.

ACOG 2026: Genevieve Neal-Perry, MD, discussed her clinical experience with elinzanetant for the treatment of VMS associated with menopause.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.

Hear from the presenting investigator of late-breaking research presented at ACOG 2026 that found over 80% of pregnancy-related infection deaths were preventable.

Hot flashes and night sweats are just 2 of the myriad symptoms associated with menopause. Click through a quick refresher on the transition and effective treatments.

ACOG 2026: In a nationally representative survey, 75% of women with menopausal symptoms reported sleep problems vs 49.8% without symptoms.

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.

ECHO-based menopause education improved PCP confidence and revealed gaps in sexual health, bleeding, and weight management training, according to new research.

Rachael Sood, NP-C, CDCES, outlines what the FDA clearance of Control-IQ+ for type 1 diabetes in pregnancy means for primary care practice.

Details on 11 key abstracts with clinical relevance for primary care, from menopause management to cervical cancer screening.

Real-world data show zuranolone improved postpartum depression symptoms by Day 15 with sustained benefit through Day 45.

ACP guidance recommends biennial mammography for women aged 50-74 and shared decision-making for screening in women aged 40-49.

Time constraints in diabetes visits may limit preventive care. Strategies for PCPs to balance chronic disease and screening needs.

Are preventive services falling through the cracks in diabetes care? Why role confusion across providers matters for PCPs.